De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials-Reference-Cited by-同舟云学术

De-escalation of dual antiplatelet therapy for patients with acute coronary syndrome after percutaneous coronary intervention: a network meta-analysis of randomised controlled trials

Published:2021-07-08 Issue:7 Volume:2021 Page:
ISSN:1465-1858
Container-title:Cochrane Database of Systematic Reviews
language:en
Short-container-title:

Author:

De Filippo Ovidio¹,Piroli Francesco¹,Bruno Francesco¹,Bocchino Pier Paolo¹,Saglietto Andrea¹,Franchin Luca¹,Angelini Filippo¹,Gallone Guglielmo¹,Alabed Samer²,Gasparini Mauro³,Ahmad Mahmood⁴,De Ferrari Gaetano Maria¹,D'Ascenzo Fabrizio⁵

Affiliation:

1. Division of Cardiology, Department of Internal Medicine; University of Turin; Turin Italy

2. Department of Infection, Immunity and Cardiovascular Disease; University of Sheffield; Sheffield UK

3. Dipartimento di Scienze Matematiche (DISMA); Giuseppe Luigi Lagrange, Politecnico di Torino; Torino Italy

4. Department of Cardiology; Royal Free Hospital, Royal Free London NHS Foundation Trust; London UK

5. Department of Internal Medicine; Division of Cardiology, University of Turin; Turin Italy

Publisher

Wiley

Subject

Pharmacology (medical)

Reference56 articles.

1. 2016 ACC/AHA Guideline focused update on duration of dual antiplatelet therapy in patients with Coronary Artery Disease;Levine;Journal of the American College of Cardiology,2016

2. From subclinical atherosclerosis to plaque progression and acute coronary events: JACC state-of-the-art review;Ahmadi;Journal of the American College of Cardiology,2019

3. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials;Baigent;Lancet,2009

4. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS;Baber;Journal of the American College of Cardiology,2016

5. Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient outcomes (PLATO) trial;Becker;European Heart Journal,2011